ATE169304T1 - Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung - Google Patents

Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung

Info

Publication number: ATE169304T1
Authority: AT; Austria
Prior art keywords: permeability; functional domain; bactericide; biologically active; active peptides
Prior art date: 1993-03-12

Application number

AT94911490T

Other languages

English (en)

Inventor

Roger G Ii Little

Original Assignee

Xoma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-12

Filing date

1994-03-11

Publication date

1998-08-15

1993-03-12 Priority claimed from US08/030,644 external-priority patent/US5348942A/en

1994-03-11 Application filed by Xoma Corp filed Critical Xoma Corp

1998-08-15 Application granted granted Critical

1998-08-15 Publication of ATE169304T1 publication Critical patent/ATE169304T1/de

Links

102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
230000000844 anti-bacterial effect Effects 0.000 title abstract 2
239000003899 bactericide agent Substances 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
102100033735 Bactericidal permeability-increasing protein Human genes 0.000 abstract 3
101000871785 Homo sapiens Bactericidal permeability-increasing protein Proteins 0.000 abstract 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 2
229960002897 heparin Drugs 0.000 abstract 2
229920000669 heparin Polymers 0.000 abstract 2
238000006386 neutralization reaction Methods 0.000 abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Pain & Pain Management (AREA)
Marine Sciences & Fisheries (AREA)

AT94911490T 1993-03-12 1994-03-11 Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung ATE169304T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/030,644 US5348942A (en)	1993-03-12	1993-03-12	Therapeutic uses of bactericidal/permeability increasing protein products
US9320293A	1993-07-15	1993-07-15
US18322294A	1994-01-14	1994-01-14

Publications (1)

Publication Number	Publication Date
ATE169304T1 true ATE169304T1 (de)	1998-08-15

Family

ID=27363684

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94911490T ATE169304T1 (de)	1993-03-12	1994-03-11	Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung

Country Status (10)

Country	Link
EP (1)	EP0690872B1 (de)
JP (3)	JP4139863B2 (de)
AT (1)	ATE169304T1 (de)
AU (1)	AU694108B2 (de)
CA (1)	CA2158058C (de)
DE (1)	DE69412243T2 (de)
DK (1)	DK0690872T3 (de)
ES (1)	ES2123134T3 (de)
NZ (1)	NZ263344A (de)
WO (1)	WO1994020532A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5420019A (en) *	1993-02-02	1995-05-30	Xoma Corporation	Stable bactericidal/permeability-increasing protein muteins
US5627153A (en) *	1994-01-14	1997-05-06	Xoma Corporation	Anti-fungal methods and materials
US5652332A (en) *	1993-03-12	1997-07-29	Xoma	Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5770561A (en) *	1993-07-14	1998-06-23	Xoma Corporation	Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
WO1995002414A1 (en) *	1993-07-14	1995-01-26	Xoma Corporation	Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
JPH08503490A (ja) *	1993-08-18	1996-04-16	モルフォシス・ゲゼルシャフト・フュア・プロタインオプティミールング・ミット・ベシュレンクテル・ハフツング	リポ多糖結合性および中和能のあるペプチド
EP0759774B1 (de) *	1993-09-22	2002-06-12	XOMA Technology Ltd.	Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
CA2173611C (en) *	1993-10-05	2005-07-26	Paul A. M. Van Leeuwen	Method of treating depressed reticuloendothelial system function
WO1995019180A1 (en) *	1994-01-14	1995-07-20	Xoma Corporation	Anti-gram-positive bacterial methods and materials
US5447913A (en) *	1994-03-11	1995-09-05	Xoma Corporation	Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5830860A (en) *	1994-03-24	1998-11-03	Regents Of The University Of Minnesota	Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
JPH10508576A (ja) *	1994-09-15	1998-08-25	ゾーマコーポレイション	抗真菌性ペプチド
WO1997004008A1 (en) *	1995-07-20	1997-02-06	Xoma Corporation	Anti-fungal peptides
US5851802A (en) *	1996-03-22	1998-12-22	Xoma Corporation	Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
PT914144E (pt) *	1996-05-10	2001-05-31	Univ Texas	Utilizacoes terapeuticas de produtos de proteinas bip contra a meningococcemia humana
US5741779A (en) *	1996-05-10	1998-04-21	Xoma Corporation	Antithrombotic materials and methods
CA2255539C (en) *	1996-05-23	2005-09-27	Xoma Corporation	Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
JP2000511892A (ja)	1996-05-24	2000-09-12	リージェンツオブザユニバーシティオブミネソタ	可溶性ベーターシート形成性ペプチドの合成
US5888973A (en)	1996-08-09	1999-03-30	Xoma Corporation	Anti-chlamydial uses of BPI protein products
US6482796B2 (en)	1996-11-01	2002-11-19	Xoma Corporation	Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) *	1997-06-20	2000-07-25	Xoma	Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
CA2298101A1 (en) *	1997-07-31	1999-02-11	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Novel synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome
US6013631A (en) *	1998-06-19	2000-01-11	Xoma Corporation	Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6242219B1 (en)	1999-03-18	2001-06-05	Xoma (Us) Llc	Methods for recombinant peptide production
DE60008749T2 (de) *	1999-06-25	2005-03-10	Xoma Technology Ltd., Berkeley	Therapeutische peptide aus untersequenzen von bpi
US6423825B1 (en)	1999-06-25	2002-07-23	Xoma Technology Ltd.	Therapeutic derivative compounds derived from domain II of bactericidal/permeability-increasing protein
US6515104B1 (en)	1999-06-25	2003-02-04	Xoma Technology Ltd.	Therapeutic peptide-based constructs derived from domain II of bactericidal/permeability-increasing protein
WO2001003724A1 (en) *	1999-07-12	2001-01-18	Xoma Technology Ltd.	Therapeutic uses of bpi protein products for inhibiting h+/k+ atpase activity
CA2476427A1 (en)	2002-02-20	2003-08-28	Regents Of The University Of Minnesota	Partial peptide mimetics and methods
DK1492874T3 (da)	2002-03-29	2011-03-14	Xoma Technology Ltd	Multigene vektorplasmider og fremgangsmåder til forøgelse af ekspressionen af rekombinante polypeptider
SE0301431D0 (sv) *	2003-05-19	2003-05-19	Dermagen	Novel antimicrobial peptides
US7878644B2 (en)	2005-11-16	2011-02-01	Gerber Scientific International, Inc.	Light cure of cationic ink on acidic substrates
GB201319621D0 (en) *	2013-11-06	2013-12-18	Norwegian University Of Science And Technology	Antimicrobial agents and their use in therapy
GB201319620D0 (en)	2013-11-06	2013-12-18	Norwegian University Of Science And Technology	Immunosuppressive agents and their use in therapy
GB201507722D0 (en)	2015-05-06	2015-06-17	Norwegian Univ Sci & Tech Ntnu	Anti-bacterial agents and their use in therapy
GB201507723D0 (en) *	2015-05-06	2015-06-17	Norwegian Univ Sci & Tech Ntnu	Anti-bacterial agents and their use in therapy
CN115894623B (zh) *	2022-12-20	2025-05-13	中国科学院昆明动物研究所	一种具有双重调节dbh和ddc酶活性功能的多肽nr6及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0220308A1 (de) *	1985-04-30	1987-05-06	Scripps Clinic And Research Foundation	Die endotoxische aktivität von lipopolysacchariden modulierendes akutphasenprotein, zusammensetzungen und verfahren
EP0563222B1 (de) *	1990-12-03	1998-02-25	New York University	Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke

1994
- 1994-03-11 ES ES94911490T patent/ES2123134T3/es not_active Expired - Lifetime
- 1994-03-11 DE DE69412243T patent/DE69412243T2/de not_active Expired - Lifetime
- 1994-03-11 WO PCT/US1994/002465 patent/WO1994020532A1/en not_active Ceased
- 1994-03-11 NZ NZ263344A patent/NZ263344A/xx unknown
- 1994-03-11 CA CA002158058A patent/CA2158058C/en not_active Expired - Fee Related
- 1994-03-11 AT AT94911490T patent/ATE169304T1/de not_active IP Right Cessation
- 1994-03-11 DK DK94911490T patent/DK0690872T3/da active
- 1994-03-11 JP JP52025194A patent/JP4139863B2/ja not_active Expired - Fee Related
- 1994-03-11 AU AU63988/94A patent/AU694108B2/en not_active Ceased
- 1994-03-11 EP EP94911490A patent/EP0690872B1/de not_active Expired - Lifetime
2004
- 2004-10-06 JP JP2004294373A patent/JP2005053921A/ja not_active Withdrawn
2007
- 2007-12-27 JP JP2007338237A patent/JP2008101026A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP4139863B2 (ja)	2008-08-27
WO1994020532A1 (en)	1994-09-15
EP0690872B1 (de)	1998-08-05
DK0690872T3 (da)	1999-05-10
AU694108B2 (en)	1998-07-16
ES2123134T3 (es)	1999-01-01
NZ263344A (en)	1997-08-22
HK1014191A1 (en)	1999-09-24
CA2158058C (en)	2000-08-01
CA2158058A1 (en)	1994-09-15
AU6398894A (en)	1994-09-26
EP0690872A1 (de)	1996-01-10
JP2005053921A (ja)	2005-03-03
DE69412243D1 (de)	1998-09-10
DE69412243T2 (de)	1999-03-25
JP2008101026A (ja)	2008-05-01
JPH08508248A (ja)	1996-09-03

Legal Events

Date	Code	Title	Description
1999-04-15	UEP	Publication of translation of european patent specification
2009-12-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69412243D1 (de)	1998-09-10	Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
CA2181150A1 (en)	1995-07-20	Biologically Active Peptides from Functional Domains of Bactericidal/Permeability-Increasing Protein and Uses Thereof
DK1521774T3 (da)	2008-10-27	Trunkerede Tau-proteiner
BR0007597A (pt)	2001-10-16	Composição hipoalergênica contendo peptìdios tolerogênicos induzindo tolerância oral
PT749317E (pt)	2002-11-29	Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
NL300830I1 (nl)	2016-09-28	Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten
DK1025236T3 (da)	2005-10-24	Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
ATE211391T1 (de)	2002-01-15	Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
DE69840024D1 (de)	2008-10-30	Antimikrobielle Peptide, abstammend von Ubiquicidin
DE69532302D1 (de)	2004-01-22	Peptide gegen pilzen
ES2087337T3 (es)	1996-07-16	Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos.
DE60138703D1 (de)	2009-06-25	Transportpeptide abgeleitet von erns protein
ATE373091T1 (de)	2007-09-15	Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen
DE69535460D1 (de)	2007-05-24	Pharmazeutische peptide formulierungen zur behandlung von staubmilben allergie
DE60329115D1 (de)	2009-10-15	Tumorantigenprotein und dessen verwendung
DE59410423D1 (de)	2006-01-12	Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
ATE390440T1 (de)	2008-04-15	Neuroaktive peptide
KR100488038B1 (ko)	2005-05-09	기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
ATE346091T1 (de)	2006-12-15	Neues diagnostisches reagens und kit zur erkennung von rickettsiose
BG101846A (bg)	1998-07-31	Варианти на човешка дезоксирибонуклеаза i
ATE452903T1 (de)	2010-01-15	Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
DE69712182D1 (de)	2002-05-29	Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
DE59611330D1 (de)	2006-04-20	Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
DE60008749D1 (de)	2004-04-08	Therapeutische peptide aus untersequenzen von bpi
Critical Care Society of South Africa Working Group	2003	Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated)